Market Intelligence, CRL4 Complex Biology, and High-Purity Reagents for Molecular Glue & PROTAC Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DDB1-centric drug discovery. Select your component below for ternary complex and ubiquitination assays:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Core Adaptor | DDB1 Full-Length Recombinant Protein (High purity >95%, Endotoxin <1 EU/µg, Sequence Verified, HEK293 Expressed) | View DDB1 Products |
| Complex Partner | DDB2 Recombinant Protein (Forms UV-DDB heterodimer with DDB1, native folding) | View DDB2 Products |
| E3 Scaffold | CUL4A Recombinant Protein (Scaffold for CRL4 complex assembly with DDB1) | View CUL4A Products |
| Substrate Examples | IKZF1 Recombinant Protein (CRL4^CRBN substrate), CRBN (primary receptor), DCAF15 (alternative receptor) | View IKZF1 Products / View CRBN Products / View DCAF15 Products |
| Gene Delivery | DDB1 Promise-ORF / Lentivirus (Full-length ORF for stable cell line generation) | View DDB1 Products |
| Benchmark Antibody | Anti-DDB1 (Sequence Verified, recombinant positive control for Western/IP) | View DDB1 Products |
| Validator | DDB1 siRNA Set (For knockdown and specificity verification in cellular assays) | View DDB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation (Glue-DDB1-Substrate) | High-purity DDB1 (>95%) with validated DDB2 binding capacity; low endotoxin ensures clean SPR/BLI kinetics |
| CRL4 Complex Assembly (E3 ligase reconstitution) | CUL4A + DDB1 + RBX1 co-expression compatible; strict MW verification by Mass Spec |
| Mutant Selectivity Screening | Custom DDB1 mutants (e.g., binding pocket variants) available; Sequence-verified by Sanger sequencing |
| Ubiquitination Assay Setup | Full-length DDB1 maintains native conformation required for CRL4 E3 ligase activity |
| Cross-Species Evaluation | Human/Mouse/Cyno DDB1 ortholog proteins sequence-verified for binding comparability |
| DCAF Selectivity Screening (CRBN vs DCAF15 vs others) | Strictly verified DCAF co-complex proteins and homolog panels by mass spec |
Live DDB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DDB1-directed therapeutics is intensifying, with major players shifting focus from traditional Cereblon (CRBN)-targeting IMiDs/CELMoDs to direct DDB1 molecular glues that recruit novel substrates like TRIM24, EZH2, and SMARCA2. As first-generation CRL4 modulators reach the clinic, the next wave of R&D is targeting substrate-selective degradation and DDB1-DDB2 complex inhibitors for DNA repair blockade in solid tumors. Bypassing CRBN resistance mutations through alternative DDB1-DCAF interfaces represents a key strategy for overcoming therapeutic resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue (CRBN) | BMS, Novartis | Multiple Myeloma, MDS | CRL4-CRBN complex assembly (Need high-purity DDB1 + CRBN + CUL4A/RBX1) |
| Molecular Glue (DDB1-directed) | C4 Therapeutics, Monte Rosa, Orionis | Solid Tumors, AML | Ternary Complex SPR (Need high-purity DDB1 + substrate) |
| PROTAC (CRL4 hijacking) | Arvinas, Nurix | Oncology | CRL4 Complex Reconstitution (Need DDB1 + CUL4A + RBX1) |
| DNA Repair Inhibitor | Research Phase | Ovarian, Lung Cancer | DDB1-DDB2 Dimer Disruption Assay |
Key Mutations in DDB1
Based on UniProt Q16531, three reported mutations in the WHIKERS region (VAR_086005, VAR_086006, VAR_086007) are notable for potential impacts on molecular glue binding or adaptor function. TarMart provides custom mutant proteins for selectivity screening and resistance mechanism studies.